For optimal results, combine tirzepatide therapy with a balanced diet, regular exercise, sufficient sleep, and routine consultations with your healthcare provider
(2021) [16] in phase 3 trials observed considerable weight loss ranging from 7.0 kg to 9.5 kg with dosages of 5, 10, and 15 mg in 478 individuals with a mean age of 54.1 years
Research has shown that it can restore T-cell immunity and correct immune deficiencies
Regulatory approval was based on the comprehensive phase 3 PIONEER clinical development programme, which demonstrated the efficacy of oral semaglutide versus placebo and most active comparators in achieving glycaemic control and weight loss, with a safety profile consistent with the GLP-1RA drug class [12,13,14,15,16,17]
Our peptides are research-grade only , distinct from clinical-grade USP/EP and not for human or veterinary administration